ReviewClinical microbiology reviews2023
Biofilm antimicrobial susceptibility testing: where are we and where could we be going?
Review in Clinical microbiology reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Antibacterial and antibiofilm effects of natural phenolic acids: Insights into structure-function relationships, extracellular pH, and morphological changes.Microbiology spectrum · 2026Article
- Impact of Narrow Empiric Antibiotic Spectrum and Patient Characteristics on Clinical Outcomes in Bone and Joint Infections: A Retrospective Cohort Study.Antibiotics (Basel, Switzerland) · 2026Article
- Mapping the global landscape of biofilm-associated antimicrobial resistance (1992-2025).Biofilm · 2026Article
- When Culture Results Don't Tell the Whole Story: A Practical Review of Antibiotics Pitfalls for Clinical Decision-Making.Infectious diseases and therapy · 2026Review
- Experimental evolution reveals adaptive pathways to reduced antibiotic susceptibility inMicrobiology (Reading, England) · 2026Article
- Staphylococcal proliferation on skin models to investigate novel anti-infective treatments against dysbiosis.Bioengineering & translational medicine · 2026Article
- Antibiotic Adjuvant Potential of Selected Essential Oil Components Against Respiratory Pathogens: From Planktonic Synergy to Early-Stage Biofilm Inhibition.Antibiotics (Basel, Switzerland) · 2026Article
- Detection to Disruption: A Comprehensive Review of Bacterial Biofilms and Therapeutic Advances.Antibiotics (Basel, Switzerland) · 2026Review
- Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape.Journal of clinical microbiology · 2026Review
- Assessment of the effect of culture components of clinical Pseudomonas aeruginosa isolates on vancomycin eradication of Staphylococcus aureus mature biofilms.BMC research notes · 2026Article
- Natural-Compound Adjuvants Dismantle Candida Biofilms: Mechanisms, Design Rules, and Biofilm-Aware Pharmacology.Current microbiology · 2026Review
- Novel lytic phages improve the antibiofilm activity of dalbavancin, daptomycin, and fosfomycin against vancomycin-resistant enterococci.Microbiology spectrum · 2026Article
- UnderstandingMicroorganisms · 2026Review
- Antibiotic resistance inFrontiers in microbiology · 2026Review
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- Genome-informed metabolomic re-analysis identifies serum-associated amino acid signatures in sepsis-associated bacterial pathogens.Frontiers in medicine · 2026Article
- Serovar-Dependent Gene Regulation and Antimicrobial Tolerance inAntibiotics (Basel, Switzerland) · 2025Article
- A model, mixed-species urinary catheter biofilm derived from spinal cord injury patients.Biofilm · 2025Article
- Article
- Harnessing machine learning to predict antibiotic susceptibility in Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our knowledge about the fundamental aspects of biofilm biology, including the mechanisms behind the reduced antimicrobial susceptibility of biofilms, has increased drastically over the last decades. However, this knowledge has so far not been translated into major changes in clinical practice. While the biofilm concept is increasingly on the radar of clinical microbiologists, physicians, and healthcare professionals in general, the standardized tools to study biofilms in the clinical microbiology laboratory are still lacking; one area in which this is particularly obvious is that of antimicrobial susceptibility testing (AST). It is generally accepted that the biofilm lifestyle has a tremendous impact on antibiotic susceptibility, yet AST is typically still carried out with planktonic cells. On top of that, the microenvironment at the site of infection is an important driver for microbial physiology and hence susceptibility; but this is poorly reflected in current AST methods. The goal of this review is to provide an overview of the state of the art concerning biofilm AST and highlight the knowledge gaps in this area. Subsequently, potential ways to improve biofilm-based AST will be discussed. Finally, bottlenecks currently preventing the use of biofilm AST in clinical practice, as well as the steps needed to get past these bottlenecks, will be discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.